In diffuse large B-cell lymphoma (DLBCL), the age-adjusted International Prognostic Index (aaIPI) score is currently used to predict patient outcomes and to choose the best therapeutic treatment. Body mass index (BMI) and gender are occasionally sited as prognostic factors; however, their value has never been studied in a large series of patients included in prospective clinical trials in the rituximab era. To assess the impact of BMI and gender on OS and PFS independently of the aaIPI score, we pooled 985 patients that were prospectively included in GELA studies and uniformly treated with R-CHOP. Univariate analysis indicated that high aaIPI and male gender were associated with a worse PFS, whereas high (>25) or low (<18.5) BMI scores were not. High aaIPI score was the only factor predictive for OS. In a multivariate analysis, including aaIPI score, gender, BMI, and interaction between BMI and gender, aaIPI remained the strongest predictive factor, and BMI < 18.5 was significantly associated with a worse OS but not PFS. In conclusion, in the rituximab era, the aaIPI score remains the major predictor of outcome in DLBCL patients; however, male gender and low BMI seem to impact outcome.
Introduction
DLBCL is the most frequent type of NHL. The outcome of DLBCL has been remarkably improved in younger as well as elderly patients by rituximab, a chimeric monoclonal antibody targeting the CD20 antigen. A recent update of randomised trials conducted by the GELA group and others evaluating the efficacy of rituximab in addition to CHOP or intensified CHOP (namely, ACVBP: 75 mg/m 2 doxorubicin and 1200 mg/m 2 cyclophosphamide on day 1; 2 mg/m 2 vindesine and 10 mg bleomycin on days 1 and 5;
and 60 mg/m 2 prednisone on days 1-5) demonstrated that the benefit of rituximab is maintained over the years [1] [2] [3] [4] [5] [6] [7] . Currently, R-CHOP is the standard of care for patients with newly diagnosed DLBCL [8, 9] . The International Prognostic Index (IPI) is commonly used to predict patient outcome and to stratify patients into low-and high-risk groups to choose the appropriate therapeutic treatment [10] . The IPI is based on 5 characteristics, age, performance status (PS), lactic dehydrogenase (LDH) levels, Ann Arbor stage, and 2 Lymphoma extranodal sites, and identifies 4 risk categories of patients with different predicted survival. A simplified score termed the age-adjusted IPI (aaIPI), based on the LDH level, Ann Arbor stage, and PS, has been developed and is widely used to direct therapeutic decision in both the younger and elderly patients.
Recent epidemiologic data has confirmed that lymphoma is more frequent in men than in women and that this difference increases with age and body mass index (BMI) [11, 12] . Indeed in several reports, being overweight (BMI > 25 kg/m 2 ) or obese (BMI > 30 kg/m 2 ) was associated with a higher risk of NHL compared with being of normal weight (BMI 18.5-25 kg/m 2 ) [13, 14] . Some recent reports have focused on the impact of gender or BMI on the outcomes of patients with DLBCL [15] [16] [17] [18] [19] [20] , but this question has never been addressed in a large cohort of patients previously included in prospective trials and uniformly treated with rituximab. Thus, to assess the prognostic value of male gender and BMI independently of the aaIPI score in DLBCL patients treated with the R-CHOP, we pooled 3 GELA prospective randomised phase III trials.
Patients and Methods

Patients.
Among the phase III studies prospectively conducted by the GELA in the rituximab era, we pooled patients from the LNH98-5 (patients between 60 and 80 years old, included between July 1998 and March 2000), LNH03-2B (patients between 18 and 59 years old with an aaIPI score of 1, included between December 2003 and December 2008, clinicaltrials.gov: NCT00140595), and LNH03-6B (patients between 60 and 80 years old, included between December 2003 and 2008; clinicaltrials.gov: NCT00144755) trials. To present homogenous data, the current study only included patients treated with R-CHOP in these different randomised studies. Details regarding the design and data management of the LNH98-5 [2] , LNH03-2B [8] , and LNH03-6B [21] trials have been published. These studies complied with all provisions of the Declaration of Helsinki and its current amendments and were conducted in accordance with Good Clinical Practice guidelines. The LNH98-5 and 03-2B, respectively, included 399 and 380 patients, of whom 202 and 184 were treated with R-CHOP. The LNH03-6B trial [21] included 602 patients randomised to R-CHOP treatment every 2 or 3 weeks (Figure 1 
Results
Initial Clinical Characteristics of the 985
Patients. The global population included 985 patients ( Figure 1 ). The patients' initial characteristics are described in Table 1 (a).
Patients from the LNH03-6B and 98-05 trial exhibited similar initial characteristics. Patients from the LNH03-2B study were younger and exhibited lower aaIPI scores. These patients were also less likely to exhibit elevated LDH levels, PS > 1, stage 3-4 disease, extranodal sites, high 2-microglobulin levels, or serum albumin < 35 g/L. There were no differences in B symptoms or bulk mass rates between the 3 trials. The ages, BMI, gender, and aaIPI scores for the patients in the pooled analysis are shown in Table 1 (b). There were no differences between the 3 trials with respect to the BMI subgroups, with similar median BMI values of 24.5, 24.3 and 25 kg/m 2 for the LNH 98-5, 03-2B, and 03-6B studies, respectively. Nevertheless, there were slightly fewer patients with a BMI < 18.5 in the LNH03-6B trial (1.5%) compared with the LNH03-2B or LNH98-5 studies (7.7 and 5.9%, resp.). Interestingly, although they included patients of the same age (60-80 years), the LNH98-5 trial included more women (54.5%) compared with the LNH03-6B (44.7%). This discrepancy is most likely due to the increasing difference in the incidence of lymphoma between genders. Indeed, the LNH03-6B and LNH03-2B studies were conducted during the same period of time (2003) (2004) (2005) (2006) (2007) (2008) and after the LNH98-5 study (1998) (1999) (2000) . The repartition of patients according to gender and BMI subgroup was comparable between the 3 trials.
Finally, the CR, Cru, and PR rate at end of treatment were similar between the three studies (shown in Table 2 ).
Univariate Analysis.
The results of the univariate analysis for OS and PFS are presented in Table 3 . High aaIPI score, age older than 60 years, and male gender were associated with a shorter PFS; the median PFS was 118 months for patients with low aaIPI scores versus 41 months for patients with high score ( < 0.0001, HR = 1.97, 95% CI (1.62-2.38)) and 111 months for females versus 59 months for males ( = 0.0262, HR = Figure 3 : PFS and OS according to gender in the subgroup of patients with a BMI > 25: male and female patients had a similar PFS ( = 0.31, median PFS 57 versus 90 for men and women, resp., HR = 1.14, 95% CI (0.87-1.49)) and OS ( = 0.9899, median OS 110 months and 106 months for men and women, resp.). a) and 2(b) ). Elderly patients exhibited a median PFS of 65 months versus not reached for patients younger than 60 years ( = 0.0011, HR = 1.61, 95% CI (1.207-2.148)). Low (<18.5) or high BMI (>25) had no significant impact on PFS ( = 0.74 and = 0.18, resp.). High aaIPI score and age were the two factors significantly associated with shorter OS; the median OS was 83 months for aaIPI > 1 versus not reached for aaIPI of 0-1 ( < 0.0001, HR = 2.41, 95% CI (1.92-3.01)), and the median OS was 108 months versus not reached ( < 0.0001, HR = 2.021, 95% CI (1.409-2.898)) for patients older or younger than 60 years, respectively. Nevertheless, even if not statistically significant, female tended to have a longer OS than males ( = 0.0681, HR = 1.21, 95% CI (0.99-1.50): median not reached versus 97 months for females and males, resp.). Low or high BMI had no significant impact on OS ( = 0.63 and = 0.12, resp.). Furthermore, PFS and OS were similar between obese patients (BMI > 30) and nonobese patients ( = 0.719 and = 0.069, resp.).
We then studied the effect of gender by stratifying by BMI (Table 4) . In patients with a BMI > 25 (Figures 3(a) and  3(b) ), gender had no effect on PFS; the median PFS was 57 versus 90 for men and women, respectively ( = 0.31, HR = 1.14, 95% CI (0.87-1.49)). Gender also had no effect on OS ( = 0.9899, HR = 1.002, 95% CI (0.74-1.34)); the median OS was 110 months and 106 months for men and women, respectively. In the population of patients with a normal BMI (18.5-25) (Figures 4(a) and 4(b) ), the effect of gender on OS and PFS was significantly different; the median OS was 97 months for men and not reached women ( = 0.0276, HR = 1.427, 95% CI (1.038-1.962)) and the median PFS was 64.8 months for men versus 118.3 for women ( = 0.0455, HR = 1.32, 95% CI (1.00-1.74)). In the population of patients with a BMI < 18.5 ( Figures 5(a) and 5(b) ), females tended to have a longer OS, as demonstrated by the survival curves; the median OS was 68.9 years for men versus not reached for women ( = 0.3246), although the difference was not statistically significant, likely as a result of the low number of patients. However, in this subgroup, the PFS survival curves Figure 5 : PFS and OS according to gender in the subgroup of patients with a BMI < 18.5: female patients tended to have a longer OS (median 68.9 versus NR for men and women, resp., = 0.3246), as shown by the survival curves, although the difference was not significant, most likely due to the low number of patients. However, in this subgroup, the PFS survival curves were totally stackable ( = 0.968, median OS 68 months versus NR for men and women, resp., HR = 1.024, 95% CI (0.32-3.27)). = 0.93 HR = 1.055 95% CI (0.29-3.76) * The test was performed using the 3 BMI classes: <18.5, 18.5-25, and >25. When 16.5 and 30 were used as the cut-offs, BMI had no impact on OS or PFS ( = 0.69 and 0.71, resp.). In a Cox regression model including BMI, gender, age, aaIPI score, and the interaction between BMI and gender as covariables, a high aaIPI score was the only factor associated with a worse PFS and OS. Low BMI significantly impacted OS but not PFS. The impact of gender varied with BMI. Gender had no impact on PFS in the subgroup of patients with a low BMI (<18.5); however, men with a low BMI tended to have a shorter OS than women with a BMI < 18.5. Male gender was a relevant bad prognostic factor for OS and PFS in the subgroup of patients with BMI scores between 18.5 and 25. Finally, gender was not a relevant prognostic factor in patients with a BMI > 25.
PFS according to gender stratified by age (≥60 years)
with number of subjects at risk and 95% confidence interval Female Male Logrank P = 0.0729 were comparable; the median PFS was 68 months for men and indeterminate for women ( = 0.968, HR = 1.024, 95% CI (0.32-3.27)). The survival analysis according to BMI and gender demonstrated that although the difference was not significant, male patients with a BMI < 18.5 had a shorter OS; the median OS of men with a BMI < 18.5 was 69 months compared with 97 months for men with a normal BMI, 111 months for men with a BMI > 25, 106 months for women with a BMI > 25, and not reached for women with a normal BMI or a BMI < 18.5 (data not shown). Finally, if females always exhibited a longer PFS and OS than males, the difference in PFS and OS observed between males and females was most significant in the elderly population. However, this difference was not statistically significant. Indeed, male over 60 years had a median PFS and OS of 55 months and 90.6 months, respectively, whereas women had a median PFS of 90.6 months and median OS was not reached (Figures 6(a) and 6(b) ).
Multivariate Analysis.
In a Cox regression analysis including gender, BMI, age, aaIPI score, and interaction between gender and BMI as variables, a high aaIPI score was the strongest factor independently associated with shorter OS and shorter PFS ( < 0.0001, HR = 2.287 and < 0.0001, HR = 1.926 for OS and PFS, resp.). A low BMI (<18.5) was also associated with a shorter OS ( = 0.048, HR = 1.394, 95% CI (1.00-1.94)) but not with a shorter PFS ( = 0.31). Neither age nor gender had any significant impact on OS or PFS in this multivariate analysis. The interaction between BMI and gender was also not statistically significant (Table 3 ).
Discussion
To our knowledge, this is the largest study evaluating the impact of gender and BMI independently of aaIPI score and age in patients with DLBCL who were prospectively treated with R-CHOP in phase III trials. In a univariate analysis, the aaIPI score was the only predictive factor for both OS and PFS. Gender was a relevant prognostic factor for PFS and exhibited a strong trend for OS. Interestingly, the impact of gender on PFS and OS varied with BMI. Indeed, the differences in OS and PFS were completely nonexistent in overweight women. Underweight women tended to have a longer OS than men with a BMI < 18.5 but exhibited a similar PFS.
In multivariate analysis, gender was not anymore a relevant prognostic factor for PFS and OS (even the difference was almost significant for OS, = 0.07), and aaIPI remained the strongest prognostic factor for both OS and PFS. Nevertheless, a low BMI was a relevant prognostic factor for OS independent of the aaIPI score but had no significant impact on PFS. These results emphasise the potential role of confounding factors in explaining the impact of low BMI or gender on survival. Those patients with a low BMI may die from causes not related to the lymphoma and/or from the complications of the treatment. Interestingly, male patients with a lower BMI exhibited lower albumin levels and higher creatinine levels at diagnosis, which may be the source of treatment-related toxicities. Furthermore, the population of males with a BMI < 18.5 exhibited the worst median OS (68.6 months), even if the difference was not statistically significant, most likely due to the low number of patients. These patients also more frequently exhibited low albumin levels or high creatinine levels compared with the other patients (data not shown), promoting a higher rate of complications and treatment-related toxicities.
Our results partially corroborate those from the RICOVER-60 of the DSHNHL [3] . In this study, the advantage in PFS provided by the rituximab was smaller in men than in women [22] . The authors also reported that men but not women might benefit from extended rituximab exposure [23] . Relying on this data, the German group is currently recruiting patients in a clinical trial (DSHNHL 2004-1) in which men receive a higher dosage of rituximab than do women. As in the present analysis, the CORAL study reported an effect of BMI on the impact of gender. Indeed, in their study, young women or slim women seemed to benefit more from rituximab maintenance salvage after ASCT than did men or overweighted postmenopausal women. The authors explain this difference with the hormone-related rituximab pharmacokinetic variation [24] . Other retrospective studies reported the impact of gender on the outcomes of patients treated with rituximab and chemotherapy for DLBCL or follicular lymphoma [15, 25] .
One explanation for this observed difference in outcomes between males and females may be the clearance of rituximab, which is more rapid in heavy or male patients [16, 26] . This variation has been described with other monoclonal antibodies [27] [28] [29] [30] [31] [32] . One explanation for the changes in pharmacokinetics with hormonal variation and the slower elimination of monoclonal antibodies observed in women could be an inhibition of antibody production and/or uptake for degradation by oestrogen alpha receptor stimulation [33] [34] [35] [36] . However, rituximab pharmacokinetics may not be the only key point, as this difference in outcome according to gender existed before the rituximab era and as anthracycline has also been reported to exhibit a different elimination schema according to gender [37] .
Although male gender is commonly known as an independent poor prognostic factor in haematological malignancies [38] [39] [40] and also in solid tumors [41] [42] [43] , it does not yet influence therapeutic choices. The absence of a clear relationship between worse outcomes and gender and the presence of many confounding factors may be the reason for this.
In the literature, the relationship between BMI and cancer incidence has been frequently studied. A recent review suggested a relationship between the secretion of cytokines in obese adipose tissue and the development of a microenvironment favorable to cancer proliferation and aggressiveness [44] . A prospective US study reported that the incidence of DLBCL was higher in obese patients [14, 45] . However, the impact of BMI on outcomes in NHL is not clear, as demonstrated by the controversial results in the literature. Indeed, a recent retrospective analysis in 2534 male United States veterans demonstrated that being overweight or obese was associated with a prolonged OS, even in the rituximab era [46] . This result corroborates a former retrospective study of NHL patients [18] . On the contrary, the RICOVER [3, 16] study reported that, in patients with a lower body weight, the addition of rituximab to CHOP resulted in a significant improvement in PFS but not in patients with a higher body weight. Furthermore, in a large prospective study including more than 900 000 [17] patients free from cancer and in a meta-analysis of different prospective studies [12] , a higher BMI was associated with a higher risk of death from NHL, including DLBCL.
In conclusion, male gender and low BMI may impact outcomes in DLBCL. The main message of this analysis is that based on large prospective data, gender or BMI may influence the outcomes of DLBCL patients treated with R-CHOP in the context of other confounding factors. The strongest prognostic factor impacting OS and PFS remains the aaIPI score. Therefore, relying on these data, it is too early to consider a gender-or BMI-specific therapeutic approach in DLBCL.
